Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.
Epistemonikos ID: de332cfbab8b4a315de31d51767fec59b10fda3d
First added on: May 21, 2024